- Home
- SUPV vs EOLS Comparison
SUPV vs EOLS Comparison
Compare SUPV & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUPV
- EOLS
- Stock Information
- Founded
- SUPV 1887
- EOLS 2012
- Country
- SUPV Argentina
- EOLS United States
- Employees
- SUPV N/A
- EOLS N/A
- Industry
- SUPV Commercial Banks
- EOLS Biotechnology: Pharmaceutical Preparations
- Sector
- SUPV Finance
- EOLS Health Care
- Exchange
- SUPV Nasdaq
- EOLS Nasdaq
- Market Cap
- SUPV 450.9M
- EOLS 406.9M
- IPO Year
- SUPV 2016
- EOLS 2018
- Fundamental
- Price
- SUPV $12.42
- EOLS $6.46
- Analyst Decision
- SUPV Hold
- EOLS Strong Buy
- Analyst Count
- SUPV 3
- EOLS 4
- Target Price
- SUPV $15.50
- EOLS $21.25
- AVG Volume (30 Days)
- SUPV 4.1M
- EOLS 1.0M
- Earning Date
- SUPV 11-24-2025
- EOLS 11-05-2025
- Dividend Yield
- SUPV 1.51%
- EOLS N/A
- EPS Growth
- SUPV N/A
- EOLS N/A
- EPS
- SUPV 0.09
- EOLS N/A
- Revenue
- SUPV $631,132,570.00
- EOLS $277,941,000.00
- Revenue This Year
- SUPV $20.63
- EOLS $13.68
- Revenue Next Year
- SUPV $22.47
- EOLS $27.96
- P/E Ratio
- SUPV $29.14
- EOLS N/A
- Revenue Growth
- SUPV N/A
- EOLS 17.15
- 52 Week Low
- SUPV $4.54
- EOLS $5.71
- 52 Week High
- SUPV $19.75
- EOLS $17.44
- Technical
- Relative Strength Index (RSI)
- SUPV 78.90
- EOLS 45.48
- Support Level
- SUPV $5.83
- EOLS $6.67
- Resistance Level
- SUPV $6.74
- EOLS $7.39
- Average True Range (ATR)
- SUPV 0.84
- EOLS 0.35
- MACD
- SUPV 0.74
- EOLS 0.03
- Stochastic Oscillator
- SUPV 94.48
- EOLS 37.29
About SUPV Grupo Supervielle S.A. each Representing five Class B shares
Grupo Supervielle SA offers financial products & services. The company's segments include Personal and Business Banking, Corporate Banking, Bank Treasury, Consumer Finance, Insurance, and Asset Management and other services. The company provides services to individuals, small businesses, middle-market companies, and large corporates in Argentina. The company also offers mutual fund services.
About EOLS Evolus Inc.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.